Skip to content

Opening book details…

Can I read Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced on EtoBox?

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced by Stefan D. Anker; Muhammad Shahzeb Khan; Javed Butler; Anne Pernille Ofstad; Barbara Peil; Egon Pfarr; Wolfram Doehner; Naveed Sattar; Andrew J. S. Coats; Gerasimos Filippatos; João Pedro Ferreira; Faiez Zannad; Stuart Pocock; Milton Packer is a Medicine article available to read on EtoBox.

What is Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced about?

## ABSTRACT ## Aims Baseline body mass index (BMI) and weight loss promoted by sodium–glucose cotransporter 2 inhibitors may impact outcomes in patients with heart failure with reduced ejection fraction (HFrEF). We assessed in the EMPEROR‐Reduced population treated with empagliflozin versus placebo the relationship between baseline BMI, weight loss and effects on the primary (time to first hospitalization for heart failure [HHF] or cardiovascular death) and key secondary outcomes. ## Methods and results We categorized patients according to their baseline BMI: <20 kg/m^2^ (__n__ = 180); 20 to <25 kg/m^2^ (__n__ = 1038); 25 to <30 kg/m^2^ (__n__ = 1345); 30 to <35 kg/m^2^ (__n__ = 774) and ≥35 kg/m^2^ (__n__ = 393). The treatment effect of empagliflozin on the primary outcome was consistent across all BMI categories (hazard ratios in subgroups 0.66–0.88, interaction trend __p__ = 0.32), as was the effect on total (first plus recurrent) HHF (interaction trend __p__ = 0.31). Empagliflozin reduced the rate of estimated glomerular filtration rate decline consistently across the BMI categories (interaction trend __p__ = 0.67). Overall, incidence rates of any or serious adverse events were

Who reads Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Stefan D. Anker; Muhammad Shahzeb Khan; Javed Butler; Anne Pernille Ofstad; Barbara Peil; Egon Pfarr; Wolfram Doehner; Naveed Sattar; Andrew J. S. Coats; Gerasimos Filippatos; João Pedro Ferreira; Faiez Zannad; Stuart Pocock; Milton Packer
Publisher
John Wiley & Sons, Ltd.
Published
2022
Language
EN
Field
Medicine (Health Sciences)

More by Stefan D. Anker; Muhammad Shahzeb Khan; Javed Butler; Anne Pernille Ofstad; Barbara Peil; Egon Pfarr; Wolfram Doehner; Naveed Sattar; Andrew J. S. Coats; Gerasimos Filippatos; João Pedro Ferreira; Faiez Zannad; Stuart Pocock; Milton Packer

Browse all works by Stefan D. Anker; Muhammad Shahzeb Khan; Javed Butler; Anne Pernille Ofstad; Barbara Peil; Egon Pfarr; Wolfram Doehner; Naveed Sattar; Andrew J. S. Coats; Gerasimos Filippatos; João Pedro Ferreira; Faiez Zannad; Stuart Pocock; Milton Packer